COVID-19 infection prolongs the length of hospital stay by nearly twofold for patients with myasthenia gravis (MG), according to a U.S. database study. The study, “Impact of COVID-19 infection among myasthenia gravis patients- a Cerner Real-World Data study,” was published in the journal BMC Neurology. In MG, the…
Since 2008, Rare Disease Day — the last day of February — has brought together patients, caregivers, family members, friends, and advocates from around the world to raise awareness and improve equity for the more than 7,000 known rare diseases that affect more than 300 million people. In 2022, the…
Zilucoplan, UCB’s experimental therapy, safely and effectively eases symptom severity and improves the quality of life for adults with generalized myasthenia gravis (gMG), while helping them complete daily activities, according to top-line data from the Phase 3 RAISE clinical trial. Based on these findings, indicating the trial met its…
People with myasthenia gravis (MG) who lack or have subtle symptom fluctuations may face a delayed diagnosis of the neuromuscular condition, according to a recent case series. Given such cases, the researchers suggest that patients who show symptoms reminiscent of the autoimmune disease, even without fluctuations, should be…
The risk of myasthenia gravis (MG) worsening during pregnancy is about 34%, a new study estimates. Notably, most MG pregnancies end in vaginal delivery, and the risk of preterm birth is not increased in women with the neuromuscular condition, the study also indicates. “The current study allows the…
Soleo Health, a pharmacy specializing in infusion therapies, will serve as the U.S. distributor that will administer Vyvgart (efgartigimod), the newly approved treatment for people with generalized myasthenia gravis (gMG). Argenx, the therapy’s developer, selected Soleo Health as a limited distribution partner for Vyvgart, which was approved…
Japan has approved Vyvgart (efgartigimod) to treat adults with generalized myasthenia gravis (gMG), the therapy’s developer, Argenx, announced. Vyvgart will be available to generalized MG patients, regardless of antibody status, who are refractory, which means they have failed to respond to steroids or nonsteroidal immunosuppressive therapies. The…
Tacrolimus is effective and safe as a single-agent immunotherapy for people with myasthenia gravis (MG), and its use led to minimal manifestation status in a majority of patients treated for one year in China, a study reported. Favorable responses were particularly evident in younger patients (up to age 40),…
Scientists described a new cellular model of the neuromuscular junction that could be useful for diagnosing myasthenia gravis (MG) or developing new treatments for the condition. “New approaches for the treatment of neurodegenerative diseases are sorely needed, as decades of research have resulted in limited therapeutic advances. We hope…
By analyzing available research and conducting nearly 100 interviews with patients, an international team of researchers crafted a new tool to measure the severity of myasthenia gravis (MG) based on patient experiences. Called MG Symptoms PRO, this tool has the potential to aid clinical trials by better capturing a…
Get regular updates to your inbox.
